Bevacizumab for advanced breast cancer: All tied up with a RIBBON?

Journal of Clinical Oncology

Volumn 29, Issue 10, 2011, Pages 1232-1235

  Burstein, Harold J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; NAVELBINE; PACLITAXEL; SUNITINIB;

ADD ON THERAPY; ADVANCED CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DRUG COST; DRUG INDUCED HEADACHE; DRUG SAFETY; EDITORIAL; HUMAN; HYPERTENSION; METASTASIS; NEUTROPENIA; NOSE CONGESTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DRUG COSTS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79953848263     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.2684     Document Type: Editorial

References (15)

1. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
2. Gray R, Bhattacharya S, Bowden C, et al: Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 27:4966-4972, 2009
3. Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247, 2010
4. Robert NJ, Diéras V, Glaspy J, et al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260, 2011
5. Mayer EL, Dhakil S, Patel T, et al: SABRE-B: An evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 21:2370-2376, 2010
6. Choueiri T, Mayer EL, Je Y, et al: Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol [epub ahead of print on January 4, 2011]
7. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 (Pubitemid 46224178)
8. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al: Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26:1987-1992, 2008
9. Kolata G, Pollack A: Costly cancer drug offers hope, but also a dilemma. New York Times, July 6, 2008. http://www.nytimes.com/2008/07/06/health/ 06avastin.html
10. Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al: Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation. Eur J Cancer 45:1397-1406, 2009
11. Smith IE, Pierga JY, Biganzoli L, et al: First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: Safety and efficacy in an open-label study in 2251 patients. Ann Oncol doi: 10.1093/annonc/ mdq430 [epub ahead of print on September 5, 2010]
12. Pazdur R: Memorandum to the file BLA 125 085 Avastin (bevacizumab). Silver Spring, MD, FDA Center for Drug Evaluation and Research, 2010. http:// www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/UCM237171.pdf
13. European Medicines Agency: Questions and answers on the review of Avastin (bevacizumab) in the treatment of metastatic breast cancer. London, United Kingdom, European Medicines Agency, 2010. http://www.ema.europa.eu/ docs/en-GB/document-library/Medicine-QA/2010/12/WC500099939.pdf
14. National Comprehensive Cancer Network: NCCN Guidelines for Breast Cancer updated: Bevacizumab recommendation confirmed. Fort Washington, PA, National Comprehensive Cancer Network, 2010. http://www.nccn.org/about/ news/newsinfo.asp?NewsID=259
15. National Institute for Health and Clinical Excellence: Final appraisal determination: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer. London, United Kingdom, National Institute for Health and Clinical Excellence, 2010. http://www.nice.org.uk/ nicemedia/live/12222/52017/52017.pdf